Dominion Biologicals

Since 1986, DBL has operated a fully integrated research and development department actively engaged in hybridoma research designed to replace human and animal source antibodies with murine and human monoclonal antibodies. DBL is the one of relatively few immunodiagnostic companies in blood banking with comprehensive in-house hybridoma research, development and production capabilities. DBL manufactures and markets a unique range of monoclonal antibody-based Blood Grouping Reagents under the trade name NOVACLONE. Currently, DBL holds the major Canadian Market share for its products and has a very significant presence in specific US, European, Mid-East and Asian Markets. In December 1996, DBL was purchased by Immucor Inc. (Norcross, Georgia, USA) as an independent subsidiary. Immucor is a publicly held company, with several subsidiaries throughout the world. Immucor manufactures and sells over 60 high quality products used primarily by hospital transfusion services and donor centers to classify donor and patient blood by group, to perform compatibility testing prior to transfusion, to detect and identify blood group antibodies and platelet antibodies and to detect maternal anti-fetal red cell antibodies. The company also distributes laboratory instrumentation for red cell-related serological testing. Immucor markets its products in the United States, Germany, France, Spain, Belgium, Netherlands, Portugal and Italy with its own direct sales force. Distribution in the balance of the world is through smaller established companies. DBL markets its products outside Canada through its own distributor network.